Follow The Filings

PTGX Protagonist Therapeutics Inc.

Health Care, filed as PROTAGONIST THERAPEUTICS INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q3

  • 4 Owners
  • Max 3.9%
  • $926M
  • 1 reduce 1 exit 1 small

In 2026 Q3 Polen Capital Management trimmed Protagonist Therapeutics, and Stanley Druckenmiller sold out.

Who owns this now

Largest portfolio weights among holders, up to 3.9% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Add 3.9%
  2. James Silverman 1.6%
  3. Polen Capital Management Reduce 0.03%

Who owns PTGX

Sorted by value, long equity only, as of 2026 Q3.

History
Farallon Capital Management 3.9%, was 3.6% Small add +1.4% 6,437,906 $907M History
James Silverman, Opaleye Management 1.6% Hold 100,000 $14M History
Polen Capital Management 0.03% Reduce −7.5% 20,963 $3M History
Ron Baron, BAMCO Inc. (Baron Capital) <0.01% Hold 16,000 $2.3M History
Stanley Druckenmiller, Duquesne Family Office exited 2026 Q3 Last 2026 Q2 0.49% Exit −0.49% 208,900 $26M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PTGX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PTGX insider trades
  • None no insider bought on the open market
  • $31.1M sold by 7 insiders outside a trading plan
  • $51.9M sold by 3 insiders under 10b5-1 plans
  1. Asif Ali CFO
    Planned sale
    $8.3M 58,629 shares at $141.78 50% of stake
    Traded Sep 30 Filed Oct 2
  2. Dinesh V. Ph D. Patel CEO
    Planned sale
    $18.2M 125,000 shares at $145.92 19% of stake
    Traded Sep 8–10 Filed Sep 10
  3. Dinesh V. Ph D. Patel CEO
    Planned sale
    $14.9M 100,000 shares at $148.91 16% of stake
    Traded Aug 10–11 Filed Aug 12
  4. William D. Waddill Director
    Planned sale
    $1.1M 9,000 shares at $117.94 54% of stake
    Traded Jun 23 Filed Jun 25
  5. William D. Waddill Director
    Planned sale
    $969K 9,000 shares at $107.68 54% of stake
    Traded Jun 10 Filed Jun 11
  6. William D. Waddill Director
    Planned sale
    $897K 9,000 shares at $99.64 54% of stake
    Traded May 29 Filed Jun 1
  7. Dinesh V. Ph D. Patel CEO
    Planned sale
    $7.5M 75,000 shares at $100.12 13% of stake
    Traded May 12 Filed May 14
  8. Bryan Giraudo Director
    Sale
    $5.9M 59,130 shares at $100.10
    Traded May 7–8 Filed May 11
  9. Arturo Molina MD Chief Medical Officer
    Sale
    $1.6M 15,000 shares at $104.79 15% of stake
    Traded Mar 26 Filed Mar 27
  10. Harold E. Selick Director
    Sale
    $2.5M 24,000 shares at $105.00 28% of stake
    Traded Mar 26 Filed Mar 27
  11. Asif Ali CFO
    Sale
    $2.6M 24,765 shares at $104.24 29% of stake
    Traded Mar 26 Filed Mar 27
  12. Dinesh V. Ph D. Patel CEO
    Sale
    $5.5M 54,700 shares at $101.00 9.4% of stake
    Traded Mar 24–25 Filed Mar 25
  13. Lewis T. Williams Director
    Sale
    $1.5M 18,000 shares at $82.42 70% of stake
    Traded Feb 17 Filed Feb 18
  14. William D. Waddill Director
    Sale
    $1.7M 20,000 shares at $83.68 72% of stake
    Traded Feb 6 Filed Feb 6
  15. Dinesh V. Ph D. Patel CEO
    Sale
    $4.1M 48,273 shares at $84.18 7.8% of stake
    Traded Jan 23–27 Filed Jan 27

Also filed in the last 12 months, not counted as buying or selling: 33 option exercises, 8 stock grants, 5 gifts, and 5 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
8-K 5.02,5.07,9.01
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G —
DEF 14A FORM- DEF 14A
DEFA14A
SCHEDULE 13G/A —
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$78.96M $275.19M -$130.15M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $355.58M $591.64M $577.57M
Total non-current assets * $2.37M $153.08M $90.61M
Total assets $357.95M $744.72M $668.19M
Total current liabilities $21.27M $47.4M $45.44M
Total non-current liabilities * $0M $22.03M $8.04M
Total equity $336.68M $675.3M $614.71M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$70.24M $184.15M $57.67M
Cash from investing -$39.26M -$299.48M -$49.33M
Cash from financing $170.48M $25.85M $22.86M
Net change in cash $60.98M -$89.48M $31.2M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf